Peptide
Telavancin (Vibativ)
Telavancin is a semi-synthetic lipoglycopeptide antibiotic with dual mechanism of action. FDA-approved September 2009 (cSSSI) and June 2013 (HABP/VABP). ATLAS trials (n=1794): Clinical cure 88.3% vs 87.1% vancomycin (noninferior) for cSSSI. ATTAIN trials: Approved for hospital-acquired pneumonia when alternatives not suitable. Coverage: MRSA, MSSA, Streptococci, E. faecalis. SAFETY CONCERN: Higher mortality in patients with pre-existing renal impairment; use when alternatives not suitable.
- Updated
- How we grade
- 26 studies cited
Research notice. This page is for education and research. Peptides may not be FDA-approved for human use and may only be legally available for research. Talk to a qualified clinician before considering any peptide.
- Best evidence
- Grade A
- Conditions studied
- 2
- Outcomes
- 7
- Graded outcomes
- 4030
Evidence by condition
- Strong
- Moderate
- Limited
- Very limited
General
Key findings
- Clinical Cure Rate - cSSSI
- Hospital-Acquired Pneumonia Efficacy
- Nephrotoxicity RiskWorsens (the measure goes up)
Safety notes in the studies
- Avoid in moderate-severe renal impairment unless benefit outweighs risk.
- SAFETY CONCERN: FDA black box warning for increased mortality in patients with CrCl <50 mL/min in HABP/VABP trials.
- Risk-benefit assessment required.
Studies cited
26 studies from PubMed
- Efficacy and Safety of Antibiotics in the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections: A Systematic Review and Network Meta-Analysis.
- Pharmacokinetics and safety of a single dose of telavancin in pediatric subjects 2-17 years of age.
- Telavancin pharmacokinetics in patients with chronic kidney disease receiving haemodialysis.
- Regional analysis of telavancin and comparator antimicrobial activity against multidrug-resistant Staphylococcus aureus collected in the USA 2014-2016.
- Renal Dosing of Antibiotics: Are We Jumping the Gun?
- Telavancin-associated acute kidney injury .
- Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens
- A comparison of telavancin and vancomycin for treatment of methicillin-resistant Staphylococcus aureus infections: A meta-analysis.
- Systematic Review and Meta-Analysis of the Efficacy and Safety of Telavancin for Treatment of Infectious Disease: Are We Clearer?
- Telavancin (VIBATIV) for the treatment of complicated skin and skin structure infections
- Skin and soft-tissue infections: a critical review and the role of telavancin in their treatment.
- Telavancin: a systematic review of the clinical evidence
- Glycopeptide antibiotic biosynthesis.
- Efficacy of telavancin, a lipoglycopeptide antibiotic, in experimental models of Gram-positive infection.
- Frontline antibiotic therapy.
- Stability and compatibility of antimicrobial lock solutions.
- Telavancin: a review of its use in patients with nosocomial pneumonia.
- Telavancin: a lipoglycopeptide antimicrobial for the treatment of complicated skin and skin structure infections caused by gram-positive bacteria in adults
- Telavancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA)
- Lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin
- Antibiotics for gram-positive bacterial infections: vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinones, daptomycin, dalbavancin, and telavancin.
- Telavancin and hydroxy propyl-beta-cyclodextrin clearance during continuous renal replacement therapy: an in vitro study.
- Telavancin: a novel lipoglycopeptide antibiotic
- Telavancin compared with vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms
- Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections.
- Telavancin: a novel lipoglycopeptide antimicrobial agent.